A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica)

W. M. Carroll, T. Saida, H. J. Kim, Jun-Ichi Kira, A. G. Kermode, C. P. Tsai, K. Fujihara, S. Kusunoki, M. Tanaka, K. K. Kim, D. Bates

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Definite diagnosis of inflammatory demyelinating disease (multiple sclerosis (MS) and neuromyelitis optica (NMO)) may require time, but early treatment offers the opportunity to maximize patient outcomes. The purpose of this report is to provide guidance to facilitate early treatment decisions for patients with inflammatory demyelinating disease, before definitive diagnosis. Neurology experts reviewed the existing literature and clinical evidence. A treatment decision pathway was developed, defining patients for whom first-line MS disease-modifying therapies (a) are unlikely to be effective, (b) may be effective but require careful monitoring and (c) are likely to provide benefit. This algorithm seeks to ensure that patients, particularly those in Asia, receive appropriate treatment early in inflammatory demyelinating disease.

Original languageEnglish
Pages (from-to)1371-1380
Number of pages10
JournalMultiple Sclerosis Journal
Volume19
Issue number10
DOIs
Publication statusPublished - Jan 1 2013

Fingerprint

Neuromyelitis Optica
Demyelinating Diseases
Multiple Sclerosis
Therapeutics
Neurology

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica). / Carroll, W. M.; Saida, T.; Kim, H. J.; Kira, Jun-Ichi; Kermode, A. G.; Tsai, C. P.; Fujihara, K.; Kusunoki, S.; Tanaka, M.; Kim, K. K.; Bates, D.

In: Multiple Sclerosis Journal, Vol. 19, No. 10, 01.01.2013, p. 1371-1380.

Research output: Contribution to journalReview article

Carroll, WM, Saida, T, Kim, HJ, Kira, J-I, Kermode, AG, Tsai, CP, Fujihara, K, Kusunoki, S, Tanaka, M, Kim, KK & Bates, D 2013, 'A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica)', Multiple Sclerosis Journal, vol. 19, no. 10, pp. 1371-1380. https://doi.org/10.1177/1352458512471092
Carroll, W. M. ; Saida, T. ; Kim, H. J. ; Kira, Jun-Ichi ; Kermode, A. G. ; Tsai, C. P. ; Fujihara, K. ; Kusunoki, S. ; Tanaka, M. ; Kim, K. K. ; Bates, D. / A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica). In: Multiple Sclerosis Journal. 2013 ; Vol. 19, No. 10. pp. 1371-1380.
@article{56a152397c324fe68e2e0495a36ae124,
title = "A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica)",
abstract = "Definite diagnosis of inflammatory demyelinating disease (multiple sclerosis (MS) and neuromyelitis optica (NMO)) may require time, but early treatment offers the opportunity to maximize patient outcomes. The purpose of this report is to provide guidance to facilitate early treatment decisions for patients with inflammatory demyelinating disease, before definitive diagnosis. Neurology experts reviewed the existing literature and clinical evidence. A treatment decision pathway was developed, defining patients for whom first-line MS disease-modifying therapies (a) are unlikely to be effective, (b) may be effective but require careful monitoring and (c) are likely to provide benefit. This algorithm seeks to ensure that patients, particularly those in Asia, receive appropriate treatment early in inflammatory demyelinating disease.",
author = "Carroll, {W. M.} and T. Saida and Kim, {H. J.} and Jun-Ichi Kira and Kermode, {A. G.} and Tsai, {C. P.} and K. Fujihara and S. Kusunoki and M. Tanaka and Kim, {K. K.} and D. Bates",
year = "2013",
month = "1",
day = "1",
doi = "10.1177/1352458512471092",
language = "English",
volume = "19",
pages = "1371--1380",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "10",

}

TY - JOUR

T1 - A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica)

AU - Carroll, W. M.

AU - Saida, T.

AU - Kim, H. J.

AU - Kira, Jun-Ichi

AU - Kermode, A. G.

AU - Tsai, C. P.

AU - Fujihara, K.

AU - Kusunoki, S.

AU - Tanaka, M.

AU - Kim, K. K.

AU - Bates, D.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Definite diagnosis of inflammatory demyelinating disease (multiple sclerosis (MS) and neuromyelitis optica (NMO)) may require time, but early treatment offers the opportunity to maximize patient outcomes. The purpose of this report is to provide guidance to facilitate early treatment decisions for patients with inflammatory demyelinating disease, before definitive diagnosis. Neurology experts reviewed the existing literature and clinical evidence. A treatment decision pathway was developed, defining patients for whom first-line MS disease-modifying therapies (a) are unlikely to be effective, (b) may be effective but require careful monitoring and (c) are likely to provide benefit. This algorithm seeks to ensure that patients, particularly those in Asia, receive appropriate treatment early in inflammatory demyelinating disease.

AB - Definite diagnosis of inflammatory demyelinating disease (multiple sclerosis (MS) and neuromyelitis optica (NMO)) may require time, but early treatment offers the opportunity to maximize patient outcomes. The purpose of this report is to provide guidance to facilitate early treatment decisions for patients with inflammatory demyelinating disease, before definitive diagnosis. Neurology experts reviewed the existing literature and clinical evidence. A treatment decision pathway was developed, defining patients for whom first-line MS disease-modifying therapies (a) are unlikely to be effective, (b) may be effective but require careful monitoring and (c) are likely to provide benefit. This algorithm seeks to ensure that patients, particularly those in Asia, receive appropriate treatment early in inflammatory demyelinating disease.

UR - http://www.scopus.com/inward/record.url?scp=84883164828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883164828&partnerID=8YFLogxK

U2 - 10.1177/1352458512471092

DO - 10.1177/1352458512471092

M3 - Review article

VL - 19

SP - 1371

EP - 1380

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 10

ER -